CS585

CS585 is a first-in-class, orally available small molecule that acts as a highly potent and selective agonist of the prostacyclin (IP) receptor. It is an analog of the oxidized lipid 12(S)-hydroxy-eicosatrienoic acid (12-HETrE), designed to inhibit platelet activation and thrombosis without increasing bleeding risk. Preclinical studies have demonstrated that CS585 effectively inhibits integrin activation, granule secretion, and platelet aggregation in both human blood and mouse models. Its anti-thrombotic effects are sustained for extended periods—up to 48 hours post-administration—and it shows greater selectivity and duration of action compared to existing IP receptor agonists such as selexipag or iloprost. The drug has shown efficacy via both oral and intravenous routes in preventing injury-induced thrombotic clot formation without affecting normal hemostasis or coagulation parameters. The primary indications under investigation include prevention of thrombosis, myocardial infarction (MI), stroke, venous thromboembolism (VTE), critical limb ischemia, and potentially pulmonary hypertension[1][4][5][6][7].